Drugs

Santhigram Kerala Ayurvedic Co. of U.S., Inc.

FDA issued a warning letter to Santhigram Kerala Ayurvedic Co. of U.S., Inc. (North Brunswick, NJ, United States) on May 19, 2022. Subject: Unapproved New Drugs.

From the letter: “Because they are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling.”

North Brunswick, NJ, United StatesIssued May 19, 2022Posted May 24, 2022No close-out recorded

At a glance

What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.

Violations
1 finding · 1 issue type
Cited
No CFR or ISO section
Response due
15 working days after receipt of this letter
FDA asks for
5 actions
Named as possible actions
Seizure, injunction
Issued by
Center for Drug Evaluation and Research
Published status
No close-out recorded

AI assisted findings

Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.

01Labeling, claims & marketingProducts are unapproved new drugs due to lack of general recognition of safety and effectiveness.
Because they are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling.

What FDA requested

  • Specific steps taken to address any violations
  • An explanation of each step being taken to prevent the recurrence of violations
  • Copies of related documentation
  • If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so
  • If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information

FDA Warning Letter

50 paragraphs · 14 sections

Text as published on FDA.gov, retrieved Sep 8, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)

AddressedDear Mr. Nair

1Introduction

1 paragraph

This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address http://www.santhigram.us in March 2022 and has observed that you take orders there for various ayurvedic products, including but not limited to “Smokers Kit/Respiratory Care Kit” (also referred to as “Respiratory Care Kit” on your social media websites), “Immunocare Kit,” “Dadimadi Ghrutham,” “Dasamoolarishtam,” “Maha Tiktaka Ghrutham,” “Padoladi Ghrutha,” “Ashwagandha,” “Triphala,” “Garlic,” “Eladi Taila,” “Jathyadi Ghrutham,” and “Jatyadi Keram” (hereinafter referred to as your “Santhigram ayurvedic products”). We also have reviewed your Facebook and Instagram social media websites at the Internet addresses https://www.facebook.com/santhigramusa and https://www.instagram.com/santhigramusa/, respectively; these websites direct consumers to your website at https://santhigram.us to purchase your products. In addition, we observed that your “Smokers Kit/Respiratory Care Kit” and “Immunocare Kit” are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people.1 The claims on your website and social media websites establish that your Santhigram ayurvedic products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov. Unapproved New Drugs Based on a review of your websites, your Santhigram ayurvedic products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or function of the body. Examples of claims observed on your website and social media websites that establish the intended use of your Santhigram ayurvedic products as drugs included, but are not limited to, the following:

2Smokers Kit/Respiratory Care Kit

2 paragraphs

On the product webpage for “Smokers Kit/Respiratory Care Kit,” https://www.santhigram.us/products/smokers-kit-respiratory-care-kit/pages/home:

• “SMOKERS KIT/RESPIRATORY CARE KIT[,] Category: COVID CARE KIT” • “It is designed to activate protective measures against bronchial or lung tissue damage and to energize, cleanse and soothe the body . . . This kit will Revitalize your Respiratory System” • “Agastya Rasayana is a quality remedy of traditional Ayurveda for Respiratory problems. It eases breathing, reduces chest congestion, reduces attacks of asthma, sharpens immune response in the body against microbes.” • “ANU THAILAM (Ayurvedic Nasya Oil) . . . It also helps in all types of nervous disorders, which occurs due to the dysfunction of the brain cells.” • “Talisapatradi is an ayurvedic herbal preparation in the form of powder which is highly effective in combating both upper and lower respiratory tract infections like the common cold, triggering of bronchitis, and Asthma, dry or productive cough, etc. It inhibits the growth of infections thus preventing infection and helps to treat chronic obstructive pulmonary diseases.” • “ARJUNA CAPSULES . . . helps to lower blood pressure.” • “DHANWANTARAM TABLET . . . Dhanwantaram Gulika is traditional ayurvedic medicine in tablet form used for diseases of Digestive system, Respiratory system, and Cardio-vascular system. It is used in conditions like dyspnoea [sic], anorexia, inflammatory conditions, etc. It gives relief in bloating, flatulence, hiccups, and also it helps relieve discomfort like breathlessness, acidity, nausea.”2

3Immunocare Kit

2 paragraphs

On the product webpage for “Immunocare Kit,” https://www.santhigram.us/products/immunocare-kit/pages/home:

• “Category: COVID CARE KIT” • “Chyawanprash is well-known to build stamina and muscle mass. . . . It slows down the ageing process, Increases the memory power . . . boosts your immunity level thus lower the infections and inflammations.” • “AMLA CAPSULE . . . It boosts the immune system by building the body’s natural defence [sic] to fight infections.” • “ASHWAGANDHA CAPSULE . . . It helps to . . . relieve stress, anxiety & depression.” • “Anu Thailam is one of the most effective Ayurvedic medicated oil which helps to improve memory. . . . It also helps in all types of nervous disorders, which occurs due to dysfunction of the brain cells.” • “CURCUMA LONGA CAPSULES . . . used for conditions involving pain and has excellent anti-inflammatory and antiseptic properties. It is also useful in depression, high cholesterol. Helpful in heartburn, inflammatory bowel disease, memory loss, stress and anxiety[.]”3

4Dadimadi Ghrutham

2 paragraphs

On the product webpage for “Dadimadi Ghrutham,” https://www.santhigram.us/products/dadimadi-ghrutham/pages/home:

• “It is widely used as medicine and also in preparatory procedure called snehakarma for the treatment of heart diseases, anemia, piles, spleen diseases, cough and asthma. . . . It is also used in the treatment of infertility in women.”

5Dasamoolarishtam

2 paragraphs

On the product webpage for “Dasamoolarishtam,” https://www.santhigram.us/collections/arishtam/products/dasamoolarishtam:

• “Indication: Useful in indigestion, lack of taste, respiratory conditions, fistula . . . vomiting, anemia, liver diseases, skin diseases, haemorrhoids [sic], urinary tract conditions, cough, jaundice.”

6Maha Tiktaka Ghrutham

2 paragraphs

On the product webpage for “Maha Tiktaka Ghrutham,” https://www.santhigram.us/products/maha-tiktaka-ghrutham/pages/home:

• “It is used as medicine and also in preparatory procedure called snehakarma for the treatment of skin diseases, bleeding disorders, bleeding piles, herpes, gastritis, gout, anemia, blisters, schizophrenia, jaundice, fever, heart diseases, menorrhagia. It is highly effective in chronic diseases.”

7Padoladi Grutha

2 paragraphs

On the product webpage for “Padoladi Grutha,” https://www.santhigram.us/products/padoladi-ghrutha/pages/home:

• “Patoladi Ghrita benefits: It is widely used as medicine and also in preparatory procedure called snehakarma for the treatment of abscess, fever, infections, skin diseases, diseases of ear, nose and throat and eye diseases[.] It is useful in psoriasis, eczema, dermatitis, allergic hives, tinea infection.”

8Ashwagandha

4 paragraphs

On the product webpage for “Ashwagandha,” https://www.santhigram.us/products/aswagandha/pages/home:

• “Category: SINGLE DRUG CAPSULE . . . Anxiety[,] Depression[,] Muscle fatigue and neck/back stiffness[,] Insomnia[,] Diabetic neuropathy[,] Erectile dysfunction and low sperm count, premature ejaculation . . . Benefits: Reduces bodyweight, decreases cholesterol levels”

On your Facebook and Instagram social media websites https://www.facebook.com/santhigramusa and https://www.instagram.com/santhigramusa/, respectively:

• December 4, 2020 postings: “Ashwagandha can help your body manage stress. Helps in: Anxiety[,] Stress[,] Diabetes[,] Fatigue[,] Pain[,] Rheumatoid arthritis . . . It boosts brain function . . . Fight symptoms of depression,” accompanied by a graphic including the text, “Ashwagandha . . . It can boost brain function, lower blood sugar and cortisol levels, and help fight symptoms of anxiety and depression.”

9Triphala

2 paragraphs

On the product webpage for “Triphala,” https://www.santhigram.us/products/triphala/pages/home:

• “Benefits: Triphala has several health benefits, such as; regulation of blood pressure, lowers cholesterol, solves digestive problems, reduce body weight, relief from constipation, boost energy, reduces inflammation, enhances skin, prevent cancer, stimulates hair growth and treats dandruff, prevents viral and bacterial infections and has anti-allergic properties.”

10Garlic

2 paragraphs

On the product webpage for “Garlic,” https://www.santhigram.us/products/garlic/pages/home:

• “Benefits: Useful in high cholesterol and high blood pressure, in common cold, upper respiratory tract infections, mild bronchitis, and rhinitis, and to relieve cough and congestion, atherosclerosis, enlarged prostate, diabetes, gastrointestinal (GI) disorders.”

11Eladi Taila

2 paragraphs

On the product webpage for “Eladi Taila,” https://www.santhigram.us/products/eladi-taila/pages/home:

• “Indication . . . It is used in hair treatment for skin diseases like allergic dermatitis, ring worm infection, urticaria. It is useful in scabies, erysipelas and cattarh. . . . It is used for external application for skin detox treatment. It is used in defective teeth, diseases of gums and mouth, ear ache and boils.”

12Jathyadi Ghrutham

2 paragraphs

On the product webpage for “Jathyadi Ghrutham,” https://www.santhigram.us/products/jathyadi-ghrutham/pages/home:

• “FOR EXTERNAL USE INDICATION[,] deep seated wounds and ulcers, non healing wound with secretions. . . . Indication: Female infertility”

13Jatyadi Keram

3 paragraphs

On the product webpage for “Jatyadi Keram,” https://www.santhigram.us/products/jatyadi-keram/pages/home:

• “Indication: It heals wounds quickly. It is used to apply externally over non healing wounds, sinus, blisters, abscess, bite wounds. It is also useful in burns. It is applied over infected skin diseases such as Hand Foot and Mouth Disease, eczema, syphilis etc. Doctors prescribe this for the treatment of cracked heels, cracked nipples, External hemorrhoids, anal fissure.”

Your Santhigram ayurvedic products are also “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.

14Conclusion

4 paragraphs

This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. While FDA has mentioned specific Santhigram ayurvedic products in this letter, there are drug claims being made on your website and social media websites for a wide range of your products. As such, the cited violations in this letter should not be viewed to apply solely to the specific products mentioned in this letter. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.

This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.

Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.

Your response should refer to unique identifier CMS 625892 and be sent to U.S. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance, by email to FDAADVISORY@fda.hhs.gov.

Sincerely, /S/ Carolyn E. Becker Director Office of Unapproved Drugs and Labeling Compliance Office of Compliance Center for Drug Evaluation and Research Food and Drug Administration

1There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https://www.phe.gov/emergency/news/healthactions/phe/Pages/default.aspx. In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https://trumpwhitehouse.archives.gov/presidentialactions/proclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak/. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.

2Similar claims, including images of your “Respiratory Care Kit,” also were found on December 1, 2020, postings on your Facebook and Instagram social media websites.

3Similar claims, including images of your “Immunocare Kit,” also were found on December 2, 2020, postings on your Facebook and Instagram social media websites.

Citations and trends

Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 3, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.

This letter cites no 21 CFR section or ISO 13485 clause.

Issue types

Record details

Issuing center
Center for Drug Evaluation and Research
Issuing office
Center for Drug Evaluation and Research
Location
North Brunswick, NJ, United States
Letter posted date
May 24, 2022
Letter issue date
May 19, 2022
Addressed to
Not recorded
Inspection dates
Not recorded
Response window
15 working days after receipt of this letter
Read the source clause
Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations.
Record length
1,875 words · 0 recorded redactions
Published status
No published close-out
FDA reference
625892
Original letter
View on FDA.gov (opens in a new tab)
Dataset last checked
Nov 11, 2026 · How this is built

A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.

See the pattern across 1,707 lettersFind letters like this →
Keep exploring

More drug letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

Find letters like this →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.